VaxartVXRT
Market Cap: $201M
About: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Employees: 109
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
5% less funds holding
Funds holding: 102 [Q1] → 97 (-5) [Q2]
5.49% less ownership
Funds ownership: 23.29% [Q1] → 17.81% (-5.49%) [Q2]
17% less call options, than puts
Call options by funds: $169K | Put options by funds: $204K
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
49% less capital invested
Capital invested by funds: $52.7M [Q1] → $27M (-$25.7M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Cheng Li 100% 1-year accuracy 1 / 1 met price target | 352%upside $4 | Outperform Initiated | 15 Aug 2024 |
Financial journalist opinion
Based on 3 articles about VXRT published over the past 30 days